JP6736574B2 - 検出方法及びキット - Google Patents
検出方法及びキット Download PDFInfo
- Publication number
- JP6736574B2 JP6736574B2 JP2017546881A JP2017546881A JP6736574B2 JP 6736574 B2 JP6736574 B2 JP 6736574B2 JP 2017546881 A JP2017546881 A JP 2017546881A JP 2017546881 A JP2017546881 A JP 2017546881A JP 6736574 B2 JP6736574 B2 JP 6736574B2
- Authority
- JP
- Japan
- Prior art keywords
- ahr
- recombinant
- dihydroindolo
- carbazole
- carboxylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001514 detection method Methods 0.000 title claims description 8
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 claims description 78
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 claims description 78
- 239000003446 ligand Substances 0.000 claims description 28
- BOPARTZFXUIWDL-UHFFFAOYSA-N ethyl 5,11-dihydroindolo[3,2-b]carbazole-12-carboxylate Chemical compound N1C2=CC=CC=C2C2=C1C=C1C3=CC=CC=C3NC1=C2C(=O)OCC BOPARTZFXUIWDL-UHFFFAOYSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 239000000523 sample Substances 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 108010029485 Protein Isoforms Proteins 0.000 claims description 10
- 102000001708 Protein Isoforms Human genes 0.000 claims description 10
- 238000001506 fluorescence spectroscopy Methods 0.000 claims description 10
- 241000252212 Danio rerio Species 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 238000004445 quantitative analysis Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 6
- 230000000185 dioxinlike effect Effects 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 238000012875 competitive assay Methods 0.000 claims description 5
- 238000000295 emission spectrum Methods 0.000 claims description 4
- 239000003344 environmental pollutant Substances 0.000 claims description 4
- 231100000719 pollutant Toxicity 0.000 claims description 4
- 239000013049 sediment Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000000159 protein binding assay Methods 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 238000004065 wastewater treatment Methods 0.000 claims description 2
- UZRJWXGXZKPSJO-UHFFFAOYSA-N 9h-carbazole-3-carboxylic acid Chemical compound C1=CC=C2C3=CC(C(=O)O)=CC=C3NC2=C1 UZRJWXGXZKPSJO-UHFFFAOYSA-N 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- LCYJXEOHLAEURY-UHFFFAOYSA-N 5,11-dihydroindolo[3,2-b]carbazole-12-carboxylic acid Chemical compound N1C2=CC=CC=C2C2=C1C=C1C3=CC=CC=C3NC1=C2C(=O)O LCYJXEOHLAEURY-UHFFFAOYSA-N 0.000 description 2
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 2
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- HIZVCIIORGCREW-UHFFFAOYSA-N 1,4-dioxene Chemical compound C1COC=CO1 HIZVCIIORGCREW-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000804 nongenotoxic Toxicity 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Description
(a)少なくとも1つの既知又は未知のAhRリガンドを含む可能性のある試料を準備するステップと、
(b)前記試料と、エチル5,11‐ジヒドロインドロ[3,2‐b]カルバゾール‐6‐カルボキシレートに既に結合され、又は、結合可能な若しくは結合前の 組換えAhRタンパク質を含む組成物とを混合するステップと、
(c)蛍光分光法によって前記試料中の前記少なくとも1つの既知又は未知のAhRリガンドの存在又は総量を判定するステップとを含む方法を提供する。
エチル5,11‐ジヒドロインドロ[3,2‐b]カルバゾール‐6‐カルボキシレートがAhRの活性部位の内部で実際に結合していることを確認するために、更なる検討を行った。本発明者らは、エチル5,11‐ジヒドロインドロ[3,2‐b]カルバゾール‐6‐カルボキシレートを置換する競合分子として既知のリガンドを添加することにより、450nmでのシグナルの減少を観察できるかどうかを試験した。エチル5,11‐ジヒドロインドロ[3,2‐b]カルバゾール‐6‐カルボキシレートは、活性部位に結合している場合にのみAhRから線形的に置換すべきである。AhRとエチル5,11‐ジヒドロインドロ[3,2‐b]カルバゾール‐6‐カルボキシレートのプレインキュベート溶液に4種の異なる競合物質を濃度を増加させながら添加した。いずれの場合も、競合物質の濃度が増加するほど450nmのピークが減少した。添加は10分ごとに行った。本アッセイは、0〜0.2μM(0〜200nM)の範囲で線形応答を示す。この濃度範囲では競合物質の存在を定量化することができる。より高い濃度の競合物質ではシグナルはそれ以上低下せず、つまり、いずれの5,11‐ジヒドロインドロ[3,2‐b]カルバゾール‐6‐カルボキシレートもAhRの活性部位から置換されている。競合物質は、反応の総体積が変化することでシグナルの変動が生じないように、ごく少量だけ加えた。450nmでのピーク強度の減少が溶媒効果によるものではないことを実証するために、緩衝液及び溶媒のみを使用して競合物質を溶解した対照試料も調製した。
Claims (15)
- エチル5,11‐ジヒドロインドロ[3,2‐b]カルバゾール‐6‐カルボキシレートの、蛍光リガンドプローブとしての使用。
- 前記エチル5,11‐ジヒドロインドロ[3,2‐b]カルバゾール‐6‐カルボキシレートを定量分析のための結合アッセイに使用する、請求項1に記載の使用。
- 組換えアリール炭化水素受容体(AhR)タンパク質と組み合わせた、請求項1又は2に記載の使用。
- 前記エチル5,11‐ジヒドロインドロ[3,2‐b]カルバゾール‐6‐カルボキシレートを競合結合アッセイに使用する、請求項1〜3のいずれかに記載の使用。
- 試料中の疑わしいアリール炭化水素受容体(AhR)リガンドの検出又は定量分析方法であって、
(a)少なくとも1つの既知又は未知のAhRリガンドを含む可能性のある試料を準備するステップと、
(b)前記試料と、エチル5,11‐ジヒドロインドロ[3,2‐b]カルバゾール‐6‐カルボキシレートに結合した又は結合可能な組換えAhRタンパク質を含む組成物とを混合するステップと、
(c)蛍光分光法によって前記試料中の前記少なくとも1つの既知又は未知のAhRリガンドの存在又は総量を判定するステップと
を含む方法。 - 前記ステップ(c)における判定は、450nm±10nmの波長における発光ピーク強度の測定に基づいて行われることを特徴とする、請求項5に記載の方法。
- 前記組換えAhRタンパク質は、ゼブラフィッシュ由来のAhRアイソフォームによりコードされる600アミノ酸組換えタンパク質であることを特徴とする、請求項5又は6に記載の方法。
- 前記組換えAhRタンパク質は、ゼブラフィッシュ由来のAhRアイソフォームの配列をコードする遺伝子を大腸菌中で発現させることによって得られることを特徴とする、請求項5〜7のいずれかに記載の方法。
- 蛍光分光法が分極蛍光分光法であることを特徴とする、請求項5〜8のいずれか一項に記載の方法。
- 前記ステップ(b)及び(c)が6時間以内に完了することを特徴とする、請求項5〜9のいずれか一項に記載の方法。
- 蛍光分光法が、親水性環境における発光スペクトルと疎水性条件における発光スペクトルとに基づいて判別されることを特徴とする、請求項5〜10のいずれか一項に記載の方法。
- 試料中の疑わしいアリール炭化水素受容体リガンドの検出又は定量分析用キットであって、2つの組成物において別々に結合した、又は単一の組成物において結合した、組換えAhRタンパク質と、エチル5,11‐ジヒドロインドロ[3,2‐b]カルバゾール‐6‐カルボキシレートとを含むキット。
- 前記組換えAhRタンパク質は、ゼブラフィッシュ由来のAhRアイソフォームによりコードされる600アミノ酸組換えタンパク質であることを特徴とする、請求項12に記載のキット。
- 前記組換えAhRタンパク質は、ゼブラフィッシュ由来のAhRアイソフォームの配列をコードする遺伝子を大腸菌中で発現させることによって得られることを特徴とする、請求項12又は13に記載のキット。
- AhRに対する結合能力を判定するための未知の化合物のスクリーニング;
AhRに結合可能なリガンドの存在を評価するための未知の化学的混合物の分析;
水、食物、若しくは堆積物からの多環式芳香族炭化水素(PAH)のスクリーニング;
水、食物、若しくは堆積物中のPAH若しくはダイオキシン様化合物のスクリーニング;
水及び廃水処理プラントでの汚染物質除去試験;
水の再利用試験;焼却炉プラントでのダイオキシン様化合物の存在試験;又は
PAH若しくはダイオキシン様化合物に暴露されたヒト若しくは動物の体液試験
のための、請求項5〜11のいずれか一項に記載の方法又は請求項12〜14のいずれか一項に記載のキットの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15158044.6A EP3064946A1 (en) | 2015-03-06 | 2015-03-06 | Detection method and kit |
EP15158044.6 | 2015-03-06 | ||
PCT/EP2016/054497 WO2016142252A1 (en) | 2015-03-06 | 2016-03-03 | Detection method and kit |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018508784A JP2018508784A (ja) | 2018-03-29 |
JP6736574B2 true JP6736574B2 (ja) | 2020-08-05 |
Family
ID=52736823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017546881A Expired - Fee Related JP6736574B2 (ja) | 2015-03-06 | 2016-03-03 | 検出方法及びキット |
Country Status (4)
Country | Link |
---|---|
US (1) | US10830772B2 (ja) |
EP (2) | EP3064946A1 (ja) |
JP (1) | JP6736574B2 (ja) |
WO (1) | WO2016142252A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106918695B (zh) * | 2017-02-21 | 2018-09-25 | 东华大学 | 一种芳香烃受体与其介导的抗体的免疫检测方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6127136A (en) * | 1995-10-23 | 2000-10-03 | Paracelsian, Inc. | Detection of dioxin-like compounds by detection of transformed Ah receptor/ARNT complex |
US6001868A (en) * | 1997-05-30 | 1999-12-14 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
JP2004201526A (ja) * | 2002-12-24 | 2004-07-22 | Toshiba Corp | 被検物質の体内残留性を検出する方法、核酸、蛋白質、細胞およびプローブ固定化チップ |
US8877434B2 (en) * | 2012-04-19 | 2014-11-04 | Hsinyu Lee | Method and system of detecting dioxin-like compounds |
WO2014050588A1 (ja) * | 2012-09-28 | 2014-04-03 | 新日鉄住金化学株式会社 | 有機電界発光素子用材料及びこれを用いた有機電界発光素子 |
-
2015
- 2015-03-06 EP EP15158044.6A patent/EP3064946A1/en not_active Withdrawn
-
2016
- 2016-03-03 WO PCT/EP2016/054497 patent/WO2016142252A1/en active Application Filing
- 2016-03-03 EP EP16707765.0A patent/EP3265816B1/en not_active Not-in-force
- 2016-03-03 JP JP2017546881A patent/JP6736574B2/ja not_active Expired - Fee Related
- 2016-03-03 US US15/556,148 patent/US10830772B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2016142252A1 (en) | 2016-09-15 |
EP3265816B1 (en) | 2018-11-28 |
US20180045731A1 (en) | 2018-02-15 |
US10830772B2 (en) | 2020-11-10 |
EP3265816A1 (en) | 2018-01-10 |
JP2018508784A (ja) | 2018-03-29 |
EP3064946A1 (en) | 2016-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Behnisch et al. | Bioanalytical screening methods for dioxins and dioxin-like compounds—a review of bioassay/biomarker technology | |
US6511815B1 (en) | Method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization | |
US20230120665A1 (en) | Composition and method for measuring thallium influx and efflux | |
Eggen et al. | The potential of mechanism-based bioanalytical tools in ecotoxicological exposure and effect assessment | |
Bernhard et al. | Two novel real time cell-based assays quantify beta-blocker and NSAID specific effects in effluents of municipal wastewater treatment plants | |
JP3887670B2 (ja) | タンパク質またはペプチド間の結合を測定するための蛍光強度法 | |
JP6736574B2 (ja) | 検出方法及びキット | |
Song et al. | A dual-state-emission chalcone-based supramolecular probe for ratiometric detection of penconazole in environmental samples | |
US20090113563A1 (en) | Probe for detecting nuclear receptor agonist or antagonist and method for screening agonist or antagonist to nuclear receptor with the use of the same | |
JP2010520759A (ja) | 「順モード(forwardmode)」調節化合物において、ナトリウム−カルシウム交換体(NCX)を調節する化合物を検出ための蛍光ベースのアッセイ | |
Coriano et al. | Monitoring ligand-activated protein–protein interactions using bioluminescent resonance energy transfer (BRET) assay | |
Wang et al. | Detection of target proteins by fluorescence anisotropy | |
Umezawa et al. | Methods of analysis for chemicals that promote/disrupt cellular signaling | |
Kim et al. | Dioxin-induced thrombocyte aggregation in zebrafish | |
Feltus et al. | Detection of biotin in individual sea urchin oocytes using a bioluminescence binding assay | |
JP3768916B2 (ja) | 内分泌撹乱物質のスクリーニング方法とそのためのキット | |
WO2020232350A1 (en) | Assays for synthetic cannabinoids | |
US20110117574A1 (en) | Fluorescence based assay to detect sodium/calcium exchanger "forward mode" modulating compounds | |
Frauli et al. | Molecular Biology Techniques Applied to GPCR Allosteric and Biased Ligands | |
JP2010075064A (ja) | 微量化学物質を検出するための核酸および方法 | |
Nijman et al. | A Review of In Vitro Methods for the Study of Thyroid Disrupting Chemicals | |
EMBSI | Test Substances | |
JP2003075442A (ja) | 標的物質測定試薬、それを用いた標的物質の測定方法 | |
Bilash et al. | Benzo [a] pyrene its influence on human organism and new nanophotonic detection method | |
Protein-Coupled et al. | 9 High Throughput |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181128 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191001 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190930 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200616 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200715 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6736574 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |